- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.11. | Ontada and Datavant partner to boost oncology data access | ||
| 13.11. | Pfizer considers divestiture of hospital drugs business | ||
| 12.11. | FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine | ||
| 12.11. | NHS launches "game-changer" and lifesaving anti-smoking pill | ||
| 12.11. | Are dry powder inhalers the key to sustainable respiratory care? | ||
| 12.11. | DMTs are major clinical research focus for Parkinson's disease, analysis shows | ||
| 12.11. | Uppsala and KTH Royal develop antibody for potential cancer treatment | ||
| 12.11. | IDWeek 2024: strategic approaches and challenges in mpox vaccination | ||
| 12.11. | Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo | ||
| 12.11. | FDA grants breakthrough status to J&J's nipocalimab for SjD treatment | ||
| 12.11. | Pharmaceutical Technology Excellence Awards 2024: BostonGene | ||
| 11.11. | FDA delays priority review of Neurotech's eye cell therapy implant | ||
| 11.11. | Gamma delta T cells explained: The next medical breakthrough? | ||
| 11.11. | ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m | ||
| 11.11. | AlloVir and Kalaris enter merger to advance retinal disease therapies | ||
| 11.11. | Cervical cancer: Navigating today's global clinical trial landscape | ||
| 11.11. | How to adapt to choppy waters in biotech ecosystem | ||
| 11.11. | Moderna's mRESVIA vaccine gains Health Canada approval | ||
| 11.11. | Dizal seeks FDA approval for NSCLC treatment sunvozertinib | ||
| 11.11. | Investment surges, hurdles and emerging innovations in neuroscience | ||
| 08.11. | Eisai lowers Leqembi revenue forecast after rocky entry to market | ||
| 08.11. | Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets | ||
| 08.11. | LakeShore commences BLA submission to DRAP for rabies vaccine | ||
| 08.11. | AstraZeneca and Amgen's Tezspire succeeds in Phase III nasal polyps trial | ||
| 08.11. | The fundamentals of developing parenteral drug products |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
